Short Interest in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Declines By 40.8%

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large drop in short interest in July. As of July 31st, there was short interest totaling 913,892 shares, a drop of 40.8% from the July 15th total of 1,543,826 shares. Based on an average daily trading volume, of 741,607 shares, the short-interest ratio is currently 1.2 days. Approximately 6.3% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets reduced their price target on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating for the company in a report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, AIM ImmunoTech currently has a consensus rating of “Buy” and an average target price of $9.00.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Corient Private Wealth LLC acquired a new stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned about 1.31% of AIM ImmunoTech at the end of the most recent reporting period. 12.02% of the stock is currently owned by institutional investors and hedge funds.

AIM ImmunoTech Price Performance

NYSEAMERICAN:AIM opened at $0.22 on Monday. The company’s 50 day moving average price is $0.31 and its 200-day moving average price is $0.56. AIM ImmunoTech has a 52 week low of $0.19 and a 52 week high of $2.98. The stock has a market cap of $6.69 million, a price-to-earnings ratio of -0.07 and a beta of 1.20.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.43) earnings per share for the quarter. The company had revenue of $0.03 million for the quarter. As a group, sell-side analysts anticipate that AIM ImmunoTech will post -0.63 earnings per share for the current year.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.